Jordan OKs Viagra, US/UK boycott plan

31 December 1998

Late last month, the Jordanian Health Ministry announced that it hadapproved Pfizer's impotence drug Viagra (sildenafil) as a scheduled drug, but added that sales will be delayed until the Ministry receives further documentation from Pfizer on the drug's side effects. A Ministry official, speaking on condition of anonymity, said that this is considered a formality and that the drug should be available within eight weeks of registration.

Mohammad Sabbagh, managing director of Pfizer's agent in Jordan, the Sabbagh Drug Company, said that Viagra will be sold on prescription only for 36 dinars ($50.84) for a pack of four, which is similar to the international price, reports the Associated Press.

Also in late December, the Jordanian Pharmacists Association and the Jordan Medical Association called for a boycott of pharmaceutical products made by US and UK companies, in protests against the airstrikes on Iraq. However, the boycott would not be legally binding and would exempt drugs for which no substitute is available. Because Viagra is unique it will be exempt from the boycott, JPA chairman Abdul Rahim Issa has said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight